Rapport Therapeutics (RAPP) Depreciation & Amortization (CF) (2023 - 2026)
Rapport Therapeutics (RAPP) has 4 years of Depreciation & Amortization (CF) data on record, last reported at $227000.0 in Q1 2026.
- On a quarterly basis, Depreciation & Amortization (CF) fell 6.97% to $227000.0 in Q1 2026 year-over-year; TTM through Mar 2026 was $1.0 million, a 7.41% increase, with the full-year FY2025 number at $1.0 million, up 21.22% from a year prior.
- Depreciation & Amortization (CF) reached $227000.0 in Q1 2026 per RAPP's latest filing, down from $265000.0 in the prior quarter.
- Over the last five years, Depreciation & Amortization (CF) for RAPP hit a ceiling of $265000.0 in Q4 2025 and a floor of $23000.0 in Q3 2023.
- A 4-year average of $188250.0 and a median of $223000.0 in 2024 define the central range for Depreciation & Amortization (CF).
- Peak YoY movement for Depreciation & Amortization (CF): soared 852.17% in 2024, then fell 6.97% in 2026.
- Tracing RAPP's Depreciation & Amortization (CF) over 4 years: stood at $53000.0 in 2023, then soared by 390.57% to $260000.0 in 2024, then grew by 1.92% to $265000.0 in 2025, then fell by 14.34% to $227000.0 in 2026.
- Business Quant data shows Depreciation & Amortization (CF) for RAPP at $227000.0 in Q1 2026, $265000.0 in Q4 2025, and $256000.0 in Q3 2025.